Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been assigned a consensus recommendation of “Buy” from the nineteen analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and sixteen have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $67.87.

A number of equities analysts recently commented on the company. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $70.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, July 5th. BidaskClub raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. ValuEngine raised Neurocrine Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Jefferies Group LLC reissued a “buy” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a research note on Tuesday, May 30th. Finally, Piper Jaffray Companies set a $68.00 price target on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Wednesday, May 24th.

In other news, insider Malcolm Lloyd-Smith sold 9,960 shares of the stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $53.63, for a total value of $534,154.80. Following the sale, the insider now directly owns 17,997 shares in the company, valued at $965,179.11. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Corinne H. Nevinny sold 5,000 shares of the stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $53.98, for a total value of $269,900.00. Following the completion of the sale, the director now owns 34,603 shares in the company, valued at $1,867,869.94. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,699 shares of company stock worth $3,855,122. Company insiders own 4.80% of the company’s stock.

Several large investors have recently modified their holdings of NBIX. Aperio Group LLC increased its stake in shares of Neurocrine Biosciences by 3.7% in the second quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock valued at $1,027,000 after buying an additional 789 shares during the last quarter. Handelsinvest Investeringsforvaltning increased its stake in shares of Neurocrine Biosciences by 125.4% in the second quarter. Handelsinvest Investeringsforvaltning now owns 44,400 shares of the company’s stock valued at $2,042,000 after buying an additional 24,700 shares during the last quarter. NN Investment Partners Holdings N.V. acquired a new stake in shares of Neurocrine Biosciences during the second quarter valued at $9,576,000. Handelsbanken Fonder AB increased its stake in shares of Neurocrine Biosciences by 23.3% in the second quarter. Handelsbanken Fonder AB now owns 148,000 shares of the company’s stock valued at $6,808,000 after buying an additional 28,000 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its stake in shares of Neurocrine Biosciences by 5.6% in the first quarter. Nuveen Asset Management LLC now owns 14,464 shares of the company’s stock valued at $626,000 after buying an additional 763 shares during the last quarter. Hedge funds and other institutional investors own 96.24% of the company’s stock.

Neurocrine Biosciences (NASDAQ NBIX) opened at 47.07 on Monday. Neurocrine Biosciences has a one year low of $37.35 and a one year high of $55.38. The stock’s market capitalization is $4.15 billion. The company’s 50 day moving average price is $45.94 and its 200-day moving average price is $45.82.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.23. During the same quarter in the prior year, the company earned ($0.22) earnings per share. Analysts expect that Neurocrine Biosciences will post ($2.48) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/07/24/neurocrine-biosciences-inc-nbix-given-consensus-recommendation-of-buy-by-brokerages.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.